Meta-analysis - Eltrombopag

N/ACompletedNCT01235988

GlaxoSmithKline1 enrolled

Overview

The purpose of the meta-analysis was to explore the efficacy of eltrombopag versus placebo (standard of care)

Meta-analysis of three studies: Bussell 2007 \& Bussell 2009 \& RAISE (TRA102537).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Thrombocytopaenia

Interventions

EltrombopagDRUG

Eltrombopag 50mg \& standard of care

PlaceboDRUG

Placebo + standard of care

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with ITP * Received a pre-specified treatment * Prospective clinical studies with at least 10 patients Exclusion Criteria: * Subjects with ITP due to other causes

Outcomes

Primary Outcomes

>=50 Gi/L platelet count to <400 Gi/L

Time frame: 43 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.